Lesson 4 of 10 · 18 min
Stem cells, mitosis and differentiation
Describe how stem cells arise by mitosis and differentiate into specialised cells, classify them as totipotent, pluripotent, multipotent or unipotent, and weigh the safety, ethics and efficacy of stem cell technologies.
What you will be able to do
- Describe how mitosis produces genetically identical cells, and how stem cells self-renew and differentiate.
- Explain that differentiation happens by switching genes on and off, not by losing genes.
- Distinguish totipotent, pluripotent, multipotent and unipotent stem cells, with an example of each.
- Describe how cells are reprogrammed to become pluripotent, and evaluate the safety, ethics and efficacy of stem cell technologies.
You began as a single cell, a fertilised egg (zygote) about 0.1 mm across. Today you are made of tens of trillions of cells of a couple of hundred different kinds: neurons a metre long, red blood cells without a nucleus, muscle fibres that contract, cells that secrete acid into your stomach. Every one of them came from that zygote by cell division, and every one carries the same DNA. So how did they become so different?
Definition
Stem cell
A stem cell is an unspecialised cell that can
- divide by mitosis to make more stem cells (self-renewal), and
- differentiate: develop into specialised cells.
Specialised cells usually divide rarely or not at all, so stem cells are the body's source of new cells for growth and repair.
Mitosis. Before a cell divides it copies (replicates) every chromosome. In mitosis the copies are separated so that each new nucleus receives one complete set. The cytoplasm then divides (cytokinesis), giving two daughter cells that are genetically identical to each other and to the parent cell, with the same number of chromosomes.
Mitosis has four stages:
- Prophase: the copied chromosomes condense and become visible, each as two identical sister chromatids joined at the centromere; the nuclear envelope breaks down.
- Metaphase: spindle fibres line the chromosomes up across the middle of the cell.
- Anaphase: the sister chromatids are pulled apart to opposite ends of the cell.
- Telophase: a nuclear envelope forms around each set of chromosomes.
Put these events of cell division in order.
How stem cells originate and renew. When a stem cell divides by mitosis, one daughter cell often stays a stem cell while the other begins to differentiate. In this way the supply of stem cells is kept up while new specialised cells are made. The zygote is the first stem cell of all; every other stem cell in your body comes from it by mitosis.
Key idea
Differentiation is gene expression
Every cell made by mitosis has the same genes. A cell differentiates by switching particular genes on and others off. The genes that are on decide which proteins the cell makes, and those proteins give it its structure and function: haemoglobin in a developing red blood cell, contractile proteins in a muscle cell, digestive enzymes in a pancreatic cell.
So a neuron and a skin cell from the same person contain identical DNA; they differ in which genes they use. Specialised cells of the same type then group together to form tissues.
Common mistake
Cells don't lose genes as they specialise
Students sometimes write that a muscle cell "only has muscle genes". It has every gene; most are switched off. (Mature mammalian red blood cells are an exception: they lose their whole nucleus.) The evidence comes from cloning: in 1962 John Gurdon grew tadpoles from frog eggs whose own nucleus had been replaced with one from a tadpole's specialised intestinal cell.
Potency. Stem cells differ in how many kinds of cell they can become, their potency. As an embryo develops, its cells' potency narrows step by step.
| Potency | Can become | Examples |
|---|---|---|
| Totipotent | Any cell of the body and the placenta and membranes around the embryo: a whole organism | The zygote and the cells of the first few divisions (up to about the 8-cell stage) |
| Pluripotent | Any cell of the body (from all three germ layers), but not the placenta | Embryonic stem cells from the inner cell mass of a 5-day blastocyst; induced pluripotent stem (iPS) cells |
| Multipotent | Several related cell types, within one tissue or family | Haematopoietic stem cells in bone marrow (all the blood cells: red, white, platelets); mesenchymal stem cells (bone, cartilage, fat); neural stem cells (neurons and glial cells) |
| Unipotent | Only one cell type (while still renewing themselves) | Spermatogonial stem cells (sperm); muscle satellite cells (skeletal muscle fibres); basal cells of the epidermis (keratinocytes) |
Pick a cell to see what it can become, and follow a lineage from the zygote. Then run the reprogramming of a skin cell back to an iPS cell.
Tip
Remember the order
Totipotent: total, everything including the placenta. Pluripotent: plural, many, all body cells. Multipotent: several in one family. Unipotent: one. Potency falls in that order as development goes on.
Stem cells in bone marrow produce red blood cells, several kinds of white blood cell and platelets, but no other cell types. How would you classify them?
Worked example
Classify stem cells by potency
Classify each cell as totipotent, pluripotent, multipotent or unipotent, and justify each answer.
(a) A cell from a human embryo at the 4-cell stage. (b) A cell from the inner cell mass of a 5-day blastocyst. (c) A stem cell in the bone marrow that gives rise to red blood cells, white blood cells and platelets. (d) A stem cell in the testis that produces only sperm.
Step 1: (a) 4-cell stage
Each cell of a very early embryo can still form a whole organism, including the placenta and membranes: totipotent.
Step 2: (b) Inner cell mass
These are embryonic stem cells. They can form any cell of the body but not the placenta, which forms from the outer layer of the blastocyst: pluripotent.
Step 3: (c) Bone marrow stem cell
It forms several cell types, but only blood cells: multipotent (a haematopoietic stem cell).
Step 4: (d) Testis stem cell
It forms only one cell type (and renews itself): unipotent (a spermatogonial stem cell).
Try it yourself first, then check the working one step at a time.
Answer
(a) Totipotent. (b) Pluripotent. (c) Multipotent. (d) Unipotent.
Method
Ask what the cell can become: everything including the placenta (totipotent), any body cell (pluripotent), several related types (multipotent), or one (unipotent).
Embryonic stage: the earlier, the greater the potency.
Watch out for
Calling embryonic stem cells totipotent. They cannot form the placenta.
Reprogramming cells. For decades the only source of pluripotent human cells was the inner cell mass of early embryos, left over from IVF and donated for research, which destroys the embryo. In 2006 Kazutoshi Takahashi and Shinya Yamanaka in Kyoto showed that adding just four genes (Oct3/4, Sox2, Klf4 and c-Myc) to mouse skin cells (fibroblasts) reprogrammed them into pluripotent cells. In 2007 Yamanaka's group, and separately James Thomson's group in the USA, did the same with human cells. These are induced pluripotent stem cells (iPS cells). Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine with John Gurdon "for the discovery that mature cells can be reprogrammed to become pluripotent".
Because iPS cells are pluripotent, they can in principle be grown into any specialised cell to repair or replace damaged tissue. Made from a patient's own skin or blood cells, they carry the patient's own genes. In 2014 a team at the RIKEN institute in Japan led by Masayo Takahashi transplanted the first tissue made from iPS cells, a sheet of retinal cells, into a woman with age-related macular degeneration.
| Aspect | Considerations |
|---|---|
| Safety | Leftover pluripotent cells can grow into tumours (teratomas); one reprogramming gene, c-Myc, can cause cancer, so newer methods avoid it. Cells from a donor can be rejected by the immune system, which iPS cells made from the patient avoid. Long culture can introduce mutations. Unproven "stem cell" treatments sold by some clinics have caused serious harm. |
| Ethics | Embryonic stem cells require the destruction of an early human embryo, which some people consider has moral status; iPS cells avoid this. In Australia, research on donated excess IVF embryos needs a licence from the NHMRC under the Research Involving Human Embryos Act 2002. Other issues: informed consent of donors, cost and fair access, and misleading advertising. |
| Efficacy | Haematopoietic (bone marrow) stem cell transplants are a proven treatment for leukaemia and other blood disorders, used since the late 1960s. Most other uses, including iPS-derived tissues, are still in clinical trials: they have to show that the transplanted cells survive, integrate, work and are safe in many patients. |
Give two advantages of using iPS cells made from a patient's own skin cells, rather than embryonic stem cells, to grow replacement tissue for that patient.
Worked example
Evaluate an iPS cell therapy for macular degeneration
In age-related macular degeneration, a layer of cells behind the retina (the retinal pigment epithelium) dies and central vision is lost. In 2014 researchers in Japan took skin cells from a patient, reprogrammed them into iPS cells, grew them into a sheet of retinal pigment epithelium and transplanted it into her eye. A year later the sheet was still in place, there was no sign of rejection or tumours, and her vision had stopped getting worse, though it had not improved.
Evaluate the use of iPS cells for this treatment, considering its safety, ethics and efficacy.
Step 1: Explain the biology
iPS cells are specialised cells reprogrammed to be pluripotent, so they can be differentiated into the required cell type, here retinal pigment epithelium.
Step 2: Safety
For: the cells came from the patient, so they are genetically identical to her and were not rejected; no immunosuppressive drugs were needed. No tumours were seen after a year.
Against: one patient followed for one year is far too little to rule out tumours from any cells that stayed pluripotent, or mutations introduced while the cells were grown.
Step 3: Ethics
For: no embryo was destroyed, avoiding the main objection to embryonic stem cells. The patient could give informed consent to use her own cells.
Against: an experimental treatment carries unknown risks; making cells for each patient is very expensive, raising questions of fair access.
Step 4: Efficacy
The sheet survived and the disease stopped progressing, which is encouraging. But vision did not improve, and a result in a single patient cannot show whether the treatment works in general; controlled trials with many patients are needed.
Step 5: Make a judgement
The treatment is promising, and safer and more ethically acceptable than using embryonic stem cells, but it is not yet proven safe or effective. It should continue in larger clinical trials before it is offered as a standard treatment.
"Evaluate" requires a judgement supported by the points above, not just a list.
Try it yourself first, then check the working one step at a time.
Answer
Promising: patient-derived iPS cells avoided rejection and the destruction of embryos, and the sheet survived without tumours. But one patient over one year cannot establish long-term safety (tumour risk) or efficacy (vision only stabilised), and the cost is high, so larger trials are needed before routine use.
Method
Explain the relevant biology briefly (what iPS cells are).
Give points for and against under safety, ethics and efficacy, each specific to the case.
Comment on the strength of the evidence (sample size, follow-up time).
Finish with a reasoned judgement.
Watch out for
Listing advantages and disadvantages without a final judgement.
Treating one successful case as proof that the treatment works.
Exam tip
Evaluating a technology
An "evaluate" question on stem cells wants both sides and a judgement. Organise your answer under the three headings the syllabus uses, safety, ethics and efficacy, with a specific point for each ("residual pluripotent cells can form tumours"), and finish with a reasoned conclusion ("promising, but not yet proven safe in large trials").
Summary
Mitosis produces two genetically identical daughter cells; stem cells divide by mitosis to renew themselves and to supply cells that differentiate.
Differentiation is switching genes on and off: every specialised cell has the same DNA but makes different proteins.
Totipotent: everything including the placenta (zygote, first few divisions). Pluripotent: any body cell (embryonic stem cells, iPS cells).
Multipotent: several related types (haematopoietic stem cells make all blood cells). Unipotent: one type (spermatogonial stem cells).
iPS cells are specialised cells reprogrammed to pluripotency (Takahashi and Yamanaka, 2006); they could replace damaged tissue without rejection or destroying embryos.
Judge stem cell technologies on safety (tumours, rejection), ethics (embryos, consent, access) and efficacy (proven for blood disorders, otherwise mostly in trials).
Finished the lesson?
Try the 3 quick checks above and the lesson completes itself, or mark it complete now.